SCHEMBL2302893

SCHEMBL2302893

c1ccc(-c2cccc(-c3nc(-c4cccc(-c5ccccc5)c4)nc(-c4cc(-c5cccc(-c6ccc(-c7ncccn7)cc6)c5)ccc4-c4ncccn4)n3)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
CLK4 Q9HAZ1 2/20 0.39
DYRK1A Q13627 1/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
NPC1 O15118 3/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 3/20 0.39
GLA P06280 1/20 0.39
ADRB2 P07550 1/20 0.39
GP6 Q9HCN6 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19075008 0.90 MEN1 (0.47) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL18327459 0.90 MEN1 (0.47) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL17720980 0.90 MEN1 (0.47) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL19533231 0.89 MEN1 (0.43) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL18327356 0.88 MEN1 (0.48) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL19039933 0.88 MEN1 (0.48) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL12386975 0.87 MEN1 (0.44) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL18327488 0.87 CLK4 (0.48) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL21982136 0.87 CLK4 (0.48) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL31642348 0.85 MEN1 (0.46) MAPTMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735577-B2 1,3,5-triazine derivative, process for producing same, and organic electroluminescent element comprising same as constituent component TOSOH CORPORATION (JP) 2014-05-27 US disclosed
EP-2351750-B1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME AS CONSTITUENT TOSOH CORP (JP) 2014-03-12 EP disclosed
US-20110190494-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT TOSOH CORPORATION (JP) 2011-08-04 US disclosed
EP-2351750-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT Tosoh Corporation (JP) 2011-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190494-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT ASH2L, SETDB1, KAT5 MAPT 2757/4885MEN1 2148/4885KMT2A 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.